About

VGXI, Inc. is a leading contract manufacturer of DNA-based pharmaceuticals with over 20 years of experience providing exceptional quality cGMP products for DNA vaccines, cell and gene therapies, and immunotherapies worldwide. VGXI's skilled team has an outstanding track record of success in manufacturing challenging plasmid products under cGMP conditions with exceptional yield, quality, and prompt delivery. The VGXI Production Services include: High purity plasmid DNA preparations for pre-clinical research, Highly documented (HD) plasmid DNA for toxicology studies or cGMP virus production, and cGMP plasmid DNA for clinical through commercial supply. Additional support provided: Fermentation and Purification Process Development and Optimization, GMP Cell Banking, GMP Fill/Finish, QC Release and Stability Testing, and CMC Support. About VGXI, Inc VGXI is a leader in plasmid DNA contract manufacturing, with 20+ years of experience providing high quality products to biomedical researchers worldwide. We support clients that develop DNA vaccines, immunotherapies, cell therapies, and gene therapies. VGXI’s manufacturing process and quality controls are coupled to a continuous, low-shear AIRMIX® patented lysis technology, and proprietary purification processes that provide highly supercoiled plasmid production and exceptional purity. VGXI’s portfolio includes high quality plasmid for preclinical research, Highly Documented (HD) plasmid as a critical raw material for GMP viral vector production or pharm/tox studies, cGMP plasmid DNA for clinical utilization through commercial supply, and custom services. About VGXI, Inc. VGXI is a leader in plasmid DNA contract manufacturing, with 20+ years of experience providing high quality products to biomedical researchers worldwide. We support clients that develop DNA vaccines, immunotherapies, cell therapies, and gene therapies. VGXI’s manufacturing process and quality controls are coupled to a continuous, low-shear AIRMIX® patented lysis technology, and proprietary purification processes that provide highly supercoiled plasmid production and exceptional purity. VGXI’s portfolio includes high quality plasmid for preclinical research, Highly Documented (HD) plasmid as a critical raw material for GMP viral vector production or pharm/tox studies, cGMP plasmid DNA for clinical utilization through commercial supply, and custom services. VGXI is a leading-edge CDMO dedicated to revolutionizing the biopharmaceutical industry with best-in-class nucleic acid-based products and services. We deliver manufacturing excellence in state-of-the-art facilities with the agility and scale to meet projects of all sizes to serve the global community of next-generation therapeutic developers.